Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Decrease of synchronization measures during a pre-ictal interval. by Christian Meisel (46720)

“…Averages over the first 150000 sample points of each time series indicate a distinct decrease of each synchronization measure during the pre-ictal interval (bottom row). …”

Stroma decreases spheroid size by decreasing cell width. by Karen F. Chambers (224337)

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…<p>(A) RFF is decreased by alterations in heart rate. …”

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

PowerPoint Slides for: Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis by Bushinsky D.A. (3246690)

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

mGluR5 receptor decreased glycinergic currents. by Zi-Yang Zhang (4988555)

“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”

SDG decreases iron-induced oxidative stress in H9c2 cells. by Stephanie Puukila (568109)

H₂O₂-induced mitochondrial size decrease is prevented by WY pre-treatment in hippocampal neurons. by Juan M. Zolezzi (586604)

Mean and standard deviation values for the Impulse during the first 50 ms of stance (Imp50) during running shod (SH) and barefoot (BF), in both PRE and POST training, where (<sup>a... by Ana Paula da Silva Azevedo (3373688)

Subjects:

Fluid loss and hydration in CON (n = 22) and HOT (n = 17) surgeries; Decrease in body mass in kg (A), decrease in body mass in % of total body mass (B), rate of decrease in body ma... by Zehra Palejwala (7507409)

Pretreatment with SDG prevents iron induced decrease in H9c2 cell size. by Stephanie Puukila (568109)

SDG decreases iron-induced MMP gene expression in H9c2 cells. by Stephanie Puukila (568109)

Topography of the relationship between the change in alpha power decrease and the change in M50 gating ratio. by Tzvetan Popov (315385)

“…B: Relationship between change in alpha power decrease (abscissa, negative values indicate improvement) and pre-to-post-training change in M50 gating ratio (ordinate, positive values indicate changes towards normal, that is, smaller gating ratio) by patient training group based on the ROI in 4A.…”

Revisiting the sealed heating method–heating cells in a low volume decreases nuclear Chk1. by Andrew J. Massey (239469)

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. by Mariam El-Ashmawy (678638)

“…<p>CDDO-Me decreases radiation-induced DNA damage in the alkaline comet assay in bronchial and mammary epithelial cells as well as human lymphocytes. …”

Patient characteristics by medical conditions pre-and post-prescription law. by Megan Armstrong (1782073)

Subjects: